08 jun: Det bølgende hus
10 jun: Overskud i APM´s containerforretning
09-06-2012 00:07:00

UPDATE: J&J to Record $600 Million Charge Due to Outstanding Lawsuits

Relateret indhold

--J&J to take litigation charge of about $600 million in second quarter

--Charge deals with litigation surrounding drugs Risperdal, Invega and Natrecor

--Took $1.1 billion litigation charge in the fourth quarter of 2011

(Updated to include details of previous litigation charge in the third paragraph.)

By Ben Fox Rubin

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

In the fourth quarter, J&J recorded a $1.1 billion charge related to litigation settlements. At the time, Chief Financial Officer Dominic Caruso said the litigation costs were primarily linked to Risperdal. The company didn't have a similar charge in its April first-quarter report.

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

J&J also has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

--Anjali Athavaley contributed to this report.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 18:07 ET (22:07 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Vind: Tyrkiet åbner op bud på 1,2 GW havvind

22-06-2018 12:08:41
Tyrkiet har lanceret landets første budrunde på havvindenergi og har allokeret en kapacitet på 1,2 gigawatt til formålet. Myndighederne har fastlagt et loft for budprisen på 80 dollar per megawatt-time, og interesserede selskaber og konsortier skal senest 23. oktober indlevere deres bud. Støtten vil blive givet i form af en elsalgsaftale for de første 50 terawatt-timer produceret energi, skriver R..

Unibrew/Danske: Kursmålet løftes til 525 kr.

22-06-2018 10:45:53
Royal Unibrews opjustering torsdag eftermiddag har fået Danske Bank til at løfte sit kursmål for bryggeriaktien til 520 kr. fra 475 kr. Anbefalingen er uændret "hold", viser data fra Bloomberg News.Unibrews nye prognose lyder på en omsætning mellem 6,8 og 7 mia. kr., et primært driftsresultat (EBITDA) på 1550 til 1625 mio. kr. og et driftsresultat efter af- og nedskrivninger på 1190 til 1265 mio. ..

Aktier/tendens: Unibrew kan ryge op i forventet rolig markedsåbning

22-06-2018 08:07:28
En opjustering fra Royal Unibrew bliver et af fokuspunkterne i fredagens tidlige danske aktiehandel, som generelt ser ud til at ville være præget af mindre bevægelser. Efter torsdagens danske børslukning, hvor det danske C25-indeks sluttede 0,2 pct. lavere i indeks 1119,14, var der ganske vist et lille fald i de amerikanske aktier på Wall Street. Men fredag morgen er der marginale plusser i handle..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
ATP reducerer bonuspotentialet til sejlivede danskere
2
Aktier/tendens: Unibrew kan ryge op i forventet rolig markedsåbning
3
EU: Grækenlands gældskrise er et afsluttet kapitel
4
Vind: Tyrkiet åbner op bud på 1,2 GW havvind
5
Aktier/middag: Unibrew indtager toppen mens Ambu igen falder tungt

Relaterede aktiekurser

Johnson & Johnson 122,84 1,1% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. juni 2018 02:52:12
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180619.1 - EUROWEB5 - 2018-06-23 02:52:12 - 2018-06-23 02:52:12 - 1 - Website: OKAY